Who Exports Sitagliptin from India — 309 Suppliers Behind a $75.8M Market
India's sitagliptin export market is supplied by 309 active exporters who collectively shipped $75.8M across 5,364 shipments. DR.REDDY'S LABORATORIES LTD leads with a 10.2% market share, followed by SANDOZ PRIVATE LIMITED and MYLAN LABORATORIES LIMITED. The top 5 suppliers together control 43.8% of total export value, reflecting a moderately competitive market structure.
Top Sitagliptin Exporters from India — Ranked by Export Value
DR.REDDY'S LABORATORIES LTD is the leading sitagliptin exporter from India, holding a 10.2% share of the $75.8M market across 5,364 shipments from 309 exporters. The top 5 suppliers — DR.REDDY'S LABORATORIES LTD, SANDOZ PRIVATE LIMITED, MYLAN LABORATORIES LIMITED, HETERO LABS LIMITED, FREDUN PHARMACEUTICALS LTD — collectively control 43.8% of total export value, indicating a competitive market. Individual shares are: DR.REDDY'S LABORATORIES LTD (10.2%), SANDOZ PRIVATE LIMITED (10.0%), MYLAN LABORATORIES LIMITED (9.2%), HETERO LABS LIMITED (7.6%), FREDUN PHARMACEUTICALS LTD (6.8%).
Top Sitagliptin Exporters from India
Ranked by export value · 309 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD HARMLESS MEDICINES, SITAGLIPTIN MYLAN 10SITAGLIPTIN BETA 100 MG FTB 98 (34620 XSITAGLIPTIN TABLETS 100MG(SITAGLIPTINE A | $7.7M | 8 | 10.2% |
| 2 | SANDOZ PRIVATE LIMITED SITAGLIPTIN SDZ 100MG 100FCT BO CA MATERMATERIAL NO. - 44101256 SITAGLIPTIN SDZSITAGLIPTIN SDZ 100MG 500FCT BO CA MATER | $7.6M | 6 | 10.0% |
| 3 | MYLAN LABORATORIES LIMITED SITAGLIPTIN / METFORMIN HCL 50/850MGSITAGLIPTIN 100MG TABLETSHARMLESS MEDICINES, SITAGLIPTIN MYLAN 10 | $7.0M | 10 | 9.2% |
| 4 | HETERO LABS LIMITED SITAGLIPTIN / METFORMIN HCL 50/850MGSITAGLIPTIN 100MG TABLETSHARMLESS MEDICINES, SITAGLIPTIN MYLAN 10 | $5.8M | 7 | 7.6% |
| 5 | FREDUN PHARMACEUTICALS LTD XIGLIP 100 - SITAGLIPTIN 100MG FILM-COATED TABLETXIGLIP 50 - SITAGLIPTIN 50MG FILM-COATED TABLET | $5.1M | 1 | 6.8% |
| 6 | ZYPHER LIFESCIENCES PRIVATE LIMITED SITARUX-M (SITAGLIPTIN PHOSPHATE & METFOSITAL M 50/1000(SITAGLIPTINE 50M METFORMSITAL 100 SITAGLIPTINE TABLETS 100MG 2X14'S | $4.8M | 1 | 6.3% |
| 7 | AUROBINDO PHARMA LTD SITAGLIPTINE VIATRIS 100 MG 28BL TAB PACSITAGLIPTIN SDZ 100MG 100FCT BO CA MATERMATERIAL NO. - 44101256 SITAGLIPTIN SDZ | $4.3M | 4 | 5.7% |
| 8 | MSN LABORATORIES PRIVATE LIMITED SITAGLIPTIN 100MG SUDAIR -SASITAGLIPTIN 100MG SUDAIR-SA | $3.2M | 1 | 4.3% |
| 9 | AUROBINDO PHARMA LIMITED SITAGLIPTINE VIATRIS 100 MG 28BL TAB PACSITAGLIPTIN SDZ 100MG 100FCT BO CA MATERMATERIAL NO. - 44101256 SITAGLIPTIN SDZ | $2.9M | 4 | 3.9% |
| 10 | BAFNA PHARMACEUTICALS LIMITED XIGLIP 100 - SITAGLIPTIN 100MG FILM-COATED TABLETXIGLIP 50 - SITAGLIPTIN 50MG FILM-COATED TABLET | $2.6M | 4 | 3.4% |
| 11 | BETA DRUGS LIMITED SITAGLIPTIN / METFORMIN HCL 50/850MGSITAGLIPTIN 100MG TABLETSSITOVA | $2.4M | 1 | 3.2% |
| 12 | SUN PHARMACEUTICAL INDUSTRIES LIMITED SITAGLIPTIN SDZ 100MG 100FCT BO CA MATERMATERIAL NO. - 44101256 SITAGLIPTIN SDZSITAGLIPTIN SDZ 100MG 500FCT BO CA MATER | $2.0M | 7 | 2.7% |
| 13 | DR REDDY S LABORATORIES LTD SITAGLIPTIN / METFORMIN HCL 50/850MGSITAGLIPTIN 100MG TABLETSHARMLESS MEDICINES, SITAGLIPTIN MYLAN 10 | $1.7M | 4 | 2.3% |
| 14 | ZENTIVA PRIVATE LIMITED SITAGLIPTINE VIATRIS 100 MG 28BL TAB PACSITAGLIPTIN TAB 100MG 28BL FR VIASITAGLIPTINE VIATRIS 100 MG 28 BL TAB PA | $1.6M | 4 | 2.1% |
| 15 | LAURUS LABS LIMITED SITAGLIPTIN SDZ 100MG 100FCT BO CA MATERMATERIAL NO. - 44101256 SITAGLIPTIN SDZSITAGLIPTIN SDZ 100MG 500FCT BO CA MATER | $1.1M | 2 | 1.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Sitagliptin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Approved | Yes | Yes | 7 | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Aurobindo Pharma Ltd. | Warning Letter (June 2019 | Yes | Yes | 41 | Received FDA warning letter in June 2019; holds WHO-GMP and EU GMP certification |
| Hetero Labs Limited | Approved | Yes | Yes | 10 | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Mylan Laboratories Limited | Approved | Yes | Yes | Not specified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | 10 | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Lupin Limited | Approved | Yes | Yes | 15 | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Zydus Lifesciences Limited | Approved | Yes | Yes | 59 | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Glenmark Pharmaceuticals Limited | Approved | Yes | Yes | 9 | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Cipla Limited | Approved | Yes | Yes | Not specified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
| Biocon Limited | Approved | Yes | Yes | Not specified | FDA-approved; holds WHO-GMP and EU GMP certifications. |
TransData Nexus reviewed the regulatory standing of 10 leading Sitagliptin exporters from India. 9 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 10 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Sitagliptin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts numerous pharmaceutical companies specializing in the synthesis of APIs, including Sitagliptin. The presence of advanced R&D facilities and a skilled workforce contributes to Hyderabad's prominence in API manufacturing. Companies like Granules India Limited, headquartered in Hyderabad, exemplify the region's capacity in producing high-quality APIs.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region is home to several leading pharmaceutical companies that excel in the development and production of finished dosage forms, including Sitagliptin tablets. Intas Pharmaceuticals, headquartered in Ahmedabad, is a notable example, producing a wide range of generic therapeutic drugs. The cluster's emphasis on formulations ensures a steady supply of high-quality Sitagliptin products for both domestic and international markets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products. This region's well-established infrastructure, including major ports and logistics facilities, facilitates the efficient export of pharmaceuticals like Sitagliptin. Companies operating in this cluster benefit from proximity to international shipping routes, enabling them to meet global demand effectively. The area's strategic location and robust export mechanisms make it a vital link in India's pharmaceutical supply chain.
4Baddi-Nalagarh — Tax Incentive Zone
Located in Himachal Pradesh, the Baddi-Nalagarh region has emerged as a significant pharmaceutical manufacturing hub, largely due to favorable tax incentives and supportive government policies. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units in the area, contributing to the production of various drugs, including Sitagliptin. The region's growth underscores the impact of policy-driven initiatives on the pharmaceutical sector.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Assess Supplier Capabilities: Evaluate potential suppliers' manufacturing capacities, quality certifications, and compliance with regulatory standards to ensure consistent product quality.
- Leverage Export Infrastructure: Utilize the logistical advantages of the Mumbai-Thane-Raigad region for efficient international distribution of Sitagliptin products.
- Monitor Regulatory Changes: Stay informed about policy developments, especially in regions like Baddi-Nalagarh, to capitalize on tax incentives and other benefits that may impact sourcing strategies.
By strategically engaging with these pharmaceutical clusters and adhering to the outlined recommendations, TransData Nexus can optimize its supply chain for Sitagliptin, ensuring reliability and efficiency in meeting global demand.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Sitagliptin exporters from India
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's acquires Mayne Pharma's U.S. generic portfolio
Dr. Reddy's Laboratories entered into a definitive agreement to acquire Mayne Pharma’s U.S. generic prescription product portfolio, which includes approximately 45 commercial products, four pipeline products, and 40 approved non-marketed products. IMPACT: This acquisition is expected to enhance Dr. Reddy's presence in the U.S. generic market, potentially increasing resources for Sitagliptin production and export.
Impact: This acquisition is expected to enhance Dr. Reddy's presence in the U.S. generic market, potentially increasing resources for Sitagliptin production and export.
Dr. Reddy's Laboratories Ltd. — Senores Pharma acquires 14 ANDAs from Dr. Reddy's
Senores Pharmaceuticals signed agreements to acquire 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories, comprising 13 approved and one pending application. IMPACT: This divestiture may allow Dr. Reddy's to reallocate resources towards core products like Sitagliptin, potentially enhancing export capabilities.
Impact: This divestiture may allow Dr. Reddy's to reallocate resources towards core products like Sitagliptin, potentially enhancing export capabilities.
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's acquires MenoLabs® women's health portfolio
Dr. Reddy's Laboratories acquired MenoLabs®, a leading women's health and dietary supplements portfolio, including seven branded products and the MenoLife® health tracker app. IMPACT: This acquisition diversifies Dr. Reddy's product offerings, potentially impacting resource allocation for Sitagliptin exports.
Impact: This acquisition diversifies Dr. Reddy's product offerings, potentially impacting resource allocation for Sitagliptin exports.
Common Questions — Sitagliptin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which sitagliptin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, DR.REDDY'S LABORATORIES LTD leads with 243 recorded shipments worth $7.7M. SANDOZ PRIVATE LIMITED (129 shipments) and MYLAN LABORATORIES LIMITED (233 shipments) are also established high-volume exporters.
Q How many sitagliptin manufacturers are there in India?
India has 309 active sitagliptin exporters with a combined export market of $75.8M across 5,364 shipments to 121 countries. The top 5 suppliers hold 43.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for sitagliptin from India?
Average FOB unit price: $6.29 per unit, ranging from $0.00 to $2133.63. Average shipment value: $14.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 309 verified Indian exporters of Sitagliptin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 5,364 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 121 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5,364 Verified Shipments
309 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists